Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
about
Metabolic complications of androgen deprivation therapy for prostate cancerHormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?Cognitive changes associated with ADT: a review of the literatureAdverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complicationsThe lived experience of physically active older prostate cancer survivors on androgen deprivation therapy.Rapid determination of vertebral fat fraction over a large range of vertebral bodies.Comparison of SEER Treatment Data With Medicare Claims.Effects of androgen deprivation on cerebral morphometry in prostate cancer patients--an exploratory study.Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancerA phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.Gonadotropin-releasing hormone analog structural determinants of selectivity for inhibition of cell growth: support for the concept of ligand-induced selective signaling.Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancerPrevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.Use of androgen deprivation therapy for metastatic prostate cancer in older men.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Cause of death in older men after the diagnosis of prostate cancer.Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.Energetics in colorectal and prostate cancer.Contemporary trends in low risk prostate cancer: risk assessment and treatmentRisk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.Effects of androgen deprivation on brain function in prostate cancer patients - a prospective observational cohort analysisReduction in physician reimbursement and use of hormone therapy in prostate cancerRadiotherapy combined with hormonal therapy in prostate cancer: the state of the art.Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.Androgen Deprivation Therapy and Future Alzheimer's Disease RiskAndrogen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) databaseObese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study.Management of complications of androgen deprivation therapy in the older man.Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.Nephrotoxicity of recent anti-cancer agents.Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer.Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancerRisk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapyThe effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review.
P2860
Q24616159-46B82EE1-E8DB-4286-AB8F-5ED795AACDAFQ26801132-B3A5051D-1C56-480F-B376-937FF03DB89AQ26822767-CEA5F38D-1F82-45DC-9CEA-72722614D356Q26852930-5E03185F-9FC7-47CF-B5C3-1F058183ADEFQ30352157-E9872973-9FFD-4836-BB85-6568ACD8CED3Q30724559-1F3E6B21-C834-4568-9254-DDDF45275C31Q30779910-1E02E228-8F08-4CC5-B86E-5A09AFCD76A3Q31127084-2F12898D-444A-459A-8F08-41CB887AA1DCQ33351115-0ECA6945-109B-43A8-8985-C70218B364C7Q33443421-CC7460BF-776C-4C60-8820-3967CB15321BQ33642701-6961F3CF-9669-4CFF-B2D2-9ED94C1CBBACQ33763924-39274761-ABD4-4093-94C7-851B2FFC156BQ33819138-40814553-7B1A-40E7-969E-C9778D3B08CDQ33877542-4C55F76A-704D-4BC4-94C1-B7F02C30D1B9Q33926384-6871D595-58F7-48E1-83A9-810ECC146518Q33977514-8CD9FCD8-C749-45DF-86F3-946705FFD96AQ33977523-6E66F26A-590A-43BA-8519-A1B81C215156Q34207357-B601260A-32F8-4DD6-9F92-141D6267300AQ34288796-1979BF10-F59E-4E9F-8B68-5A8DE0A898CAQ34315768-51E5390C-2E65-40F5-BFB5-349CCF32CC80Q34330041-EA8643FC-089F-401E-8597-B037B77D2C7FQ34366865-081ECD70-0A3E-425D-9EB8-E3EAF6B53941Q34394243-86279F9D-69AF-4585-A858-BE9EC525DBE8Q34406403-14F220E7-4B64-4467-8294-8EC89DE19C43Q34417815-C61C9799-00EE-4768-9FF3-498F906D987CQ34421944-BF521D44-C52F-403B-8459-18B132AEB0CAQ34497901-45445A7F-AEC5-466A-AB19-2B908125A018Q34504328-0C82DA88-0E74-4F6B-888A-AFE744FB832FQ34617924-F992D8E9-479F-4499-84AC-584DED8DCA36Q34617956-80421523-6384-45E2-A5FC-A342DC4B9C29Q34629714-791FAA5C-9FE7-4035-80F1-290F3CDF84D1Q34663266-C79BEE85-6F10-4852-9CDA-EDEC935BB1A4Q34778958-9F64AE68-E381-4D23-BF68-B18F56988BAEQ34782101-CB1C7404-D7E4-417C-A18C-5324FA6C7A48Q35022837-BCE684AE-92A1-4659-B38F-EB5D3531B467Q35310741-66272B0C-48AF-444B-B5FD-F4DA50E78554Q35433102-A01E7BAB-9A0D-462B-9854-35240EE797F9Q35441262-245F12D2-CD77-4EB7-ADC7-E6CD982609CCQ35635497-92C3D388-EDFF-4D9C-9954-1C7E87A7E77DQ35640064-AFD1FDF7-F996-4F20-979B-55CE080C7084
P2860
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Increasing use of gonadotropin ...... localized prostate carcinoma.
@ast
Increasing use of gonadotropin ...... localized prostate carcinoma.
@en
type
label
Increasing use of gonadotropin ...... localized prostate carcinoma.
@ast
Increasing use of gonadotropin ...... localized prostate carcinoma.
@en
prefLabel
Increasing use of gonadotropin ...... localized prostate carcinoma.
@ast
Increasing use of gonadotropin ...... localized prostate carcinoma.
@en
P2093
P356
P1433
P1476
Increasing use of gonadotropin ...... localized prostate carcinoma.
@en
P2093
Eduardo Orihuela
James S Goodwin
Jean L Freeman
Vahakn B Shahinian
Yong-fang Kuo
P304
P356
10.1002/CNCR.20955
P407
P577
2005-04-01T00:00:00Z